Metabolic abnormalities among people diagnosed with schizophrenia: A literature review and implications for mental health nurses

Journal of Psychiatric and Mental Health Nursing

Volumn 22, Issue 3, 2015, Pages 157-170

  Mcdaid, T M ^a   Smyth, S ^b  

^a HEALTH SERVICE EXECUTIVE   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Diabetes; Dyslipidaemia; Education; Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

COMORBIDITY; HUMAN; METABOLIC SYNDROME X; PROCEDURES; PSYCHIATRIC NURSING; SCHIZOPHRENIA;

COMORBIDITY; HUMANS; METABOLIC SYNDROME X; PSYCHIATRIC NURSING; SCHIZOPHRENIA;

EID: 84925347022     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/jpm.12185     Document Type: Article

References (47)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC. text review.
2. Brown I., Stride C., Psarou A., etal. (2007) Management of obesity in primary care: nurses' practices, beliefs and attitudes. Journal of Advanced Nursing 59, 329-341.
3. Citrome L., Jaffe A., Levine J., etal. (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric clients. Psychiatric Services 55, 1006-1013.
4. Cohen D., Stolk R.P., Grobbee D.E., etal. (2006) Hyperglycaemia and diabetes in clients with schizophrenia and schizoaffective disorder. Diabetes Care 29, 786-791.
5. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes (2004) Consensus statement. Diabetes Care 27, 596-601.
6. De Hert M., van Winkel R., Van Eyck D., etal. (2006a) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health 2, 14. Available at: http://www.ncbi.nlm.nih.gov.libgate.library.nuigalway.ie/pmc/articles/PMC1533826/pdf/1745-0179-2-14.pdf (accessed 26 November 2012).
7. De Hert M., van Winkel R., Van Eyck D., etal. (2006b) Prevalence of the metabolic syndrome in clients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83, 87-93.
8. De Hert M., Schreurs V., Sweers K., etal. (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research 101, 295-303.
9. Fountoulakis K.N., Siamouli M., Panagiotidis P., etal. (2010) Obesity and smoking in clients with schizophrenia, and normal controls: a case-control study. Psychiatric Research 176, 13-16.
10. Genest J., McPherson R., Frohlich J., etal. (2009) Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidaemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Canadian Journal of Cardiology 25, 567-579.
11. Ginsberg H.N. (2003) Treatment for clients with the metabolic syndrome. The American Journal of Cardiology 91 (7A), 29E-39E.
12. Grundy S.M., Cleeman J.I., Merz C.N., etal., for the Coordinating Committee of the National Cholesterol Education Program, endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation and American Heart Association (2004) Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110, 227-239.
13. Holt R. & Pevelert R. (2010) Diabetes and cardiovascular risk in serious mental illness: a missed opportunity and challenge for the future. Practice Diabetes International 27, 79-84.
14. Hsu J.H., Chien I.C., Lin C.H., etal. (2012) Hyperlipidemia in patients with schizophrenia: a national population-based study. General Hospital Psychiatry 34, 360-367.
15. Humphrey Beebe L., Smith K., Burk R., etal. (2011) Effect of a motivational intervention on exercise behaviour in persons with schizophrenia spectrum disorders. Community Mental Health Journal 47, 628-636.
16. International Diabetes Federation (2006) IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Belgium.
17. Kagal U.A., Torgal S.S., Patil N.M., etal. (2012) Prevalence of the metabolic syndrome in schizophrenic clients receiving second-generation antipsychotic agents - a cross-sectional study. Journal of Pharmacy Practice 25, 368-373.
18. Liao C.H., Chang C.S., Wei W.C., etal. (2011) Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidaemia: a population-based study. Schizophrenia Research 126, 110-116.
19. Lieberman J.A., Stroup T.S., McEvoy J.P., etal. (2005) Effectiveness of antipsychotic drugs in clients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
20. Lin C.C., Yu S.C., Wu B.J., etal. (2012) Measurement of waist circumference at different sites affects detection of abdominal obesity and metabolic syndrome among schizophrenic clients. Psychiatric Research 197, 322-326.
21. Lindenmayer J.P., Khan A., Wance D., etal. (2009) Outcome evaluation of a structured educational wellness program in clients with severe mental illness. Journal of Clinical Psychiatry 70, 1385-1396.
22. McCreadie R.G. (2003) Diet, smoking and cardiovascular risk in people with schizophrenia. British Journal of Psychiatry 183, 534-539.
23. Meyer J.M., Nasrallah H.A., McEvoy J.P., etal. (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without metabolic syndrome. Schizophrenia Research 80, 9-18.
24. Mitchell A., Vancampfort D., Sweers K., etal. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and metaanalysis. Schizophrenia Bulletin 39, 306-318.
25. Murray C.J.L. & Lopez A.D., eds (1996) The Global Burden of Disease; a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. USA: Harvard School of Public Health on Behalf of the World Health Organisation and The World Bank.
26. Nash M. (2009) Mental health nurses diabetes care skills - a training needs analysis. British Journal of Nursing 18, 626-630.
27. Nash M. (2010) Assessing nurses' propositional knowledge of physical health; a training exercise showed that staff need better education to identify clients at risk of experiencing drug reactions and to recognise undiagnosed physical disorders that may affect treatment. Mental Health Practice 14, 20-23.
28. Nasrallah H.A., Meyer J.M., Goff D.C., etal. (2006) Low rates of treatment for hypertension, dyslipidaemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86, 15-22.
29. National Cholesterol Education Program (2001) ATP III Guidelines At-A-Glance Quick Desk Reference. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf (accessed 12 November 2012).
30. National Institute for Clinical Excellence (NICE) (2010) Schizophrenia; the NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary care-Updated. Great Britain: The British Psychological Society and The Royal College of Psychiatrists.
31. Osborn D.J.P., Nazareth I., Wright C.A., etal. (2010) Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. BMC Health Services Research 10, 61.
32. Osborn D.P., Nazareth I. & King M.B. (2006) Risk for coronary heart disease in people with severe mental illness, cross sectional comparative study in primary care. British Journal of Psychiatry 118, 271-277.
33. Osborn D.P., Levy G., Nazareth I., etal. (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Archives of General Psychiatry 64, 242-249.
34. Perk J., De Backer G., Gohlke H., etal. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Council for Preventative Cardiology. Available at: http://cpr.sagepub.com/content/early/2012/06/18/2047487312450228.citation (accessed 12 October 2012).
35. Riordan H.J., Antonini P. & Murphy M.F. (2011) Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. American Health & Drug Benefits 4, 292-301.
36. San L., Arranz B., Perez V., etal. (2012) One year randomised open trial comparing olanzapine, quetiapine, risperidone and ziprasadone effectiveness in antipsychotic-naïve clients with first episode psychosis. Psychiatric Research 200, 693-701.
37. Schoepf D., Potluri R., Uppal H., etal. (2012) Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. European Psychiatry 27, 33-42.
38. Scott D. & Happell B. (2011) The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues in Mental Health Nursing 32, 589-597.
39. Subashini R., Deepa M., Padmivati R., etal. (2011) Prevalence of diabetes, obesity and metabolic syndrome among subjects with and without schizophrenia. (CURES-104). Journal of Postgraduate Medicine 57, 272-277.
40. Usher K., Foster K. & Park T. (2006) The metabolic syndrome and schizophrenia; the latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing 13, 730-734.
41. Vancampfort D., Probst M., Sweers K., etal. (2011) Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatrica Scandinavica 123, 423-430.
42. Voruganti L.P., Punthakee Z., Van Lieshout R.J., etal. (2007) Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophrenia Research 96, 215-222.
43. White J., Gray R., Swift L., etal. (2011) The serious mental illness health improvement profile [HIP]: study protocol for a cluster randomised controlled trial. Trials 12, 167. doi: 10.1186/1745-6215-12-167.
44. Wilson P.W., D'Agostine R.B., Sullivan L., etal. (2002) Overweight and obesity as determinant of cardiovascular risk: the Framingham experience. Archives of International Medicine 162, 1867-1872.
45. World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Geneva: World Health Organization.
46. World Health Organization (WHO) (2012) Mental health: schizophrenia, what is schizophrenia? Available at: http://www.who.int/mental_health/management/schizophrenia/en/ (accessed 13 October 2012).
47. Wu R.R., Zhao J.P., Liu Z.N., etal. (2006) Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Journal of Psychopharmacology 186, 572-578.